Department of Biotechnology, Assam University, Silchar, 788011, Assam, India.
Department of Biotechnology, Assam University, Silchar, 788011, Assam, India.
Comp Immunol Microbiol Infect Dis. 2021 Feb;74:101574. doi: 10.1016/j.cimid.2020.101574. Epub 2020 Nov 16.
Tuberculosis (TB) was announced as a global emergency in 1993. There was an alarming counter attack of TB worldwide. However, when it was known that TB can be cured completely, the general public became ignorant towards the infection. The pathogenic organism Mycobacterium tuberculosis continuously evolved to resist the antagonist drugs. This has led to the outbreak of resistant strain that gave rise to "Multi Drug Resistant-Tuberculosis" and "Extensively Drug Resistant Tuberculosis" that can still be cured with a lower success rate. While the mechanism of resistance proceeds further, it ultimately causes unmanageable totally drug resistant TB (TDR-TB). Studying the molecular mechanisms underlying the resistance to drugs would help us grasp the genetics and pathophysiology of the disease. In this review, we present the molecular mechanisms behind Mycobacterium tolerance to drugs and their approach towards the development of multi-drug resistant, extremely drug resistant and totally drug resistant TB.
1993 年,结核病(TB)被宣布为全球紧急情况。全球范围内出现了结核病令人震惊的反扑。然而,当人们知道结核病可以完全治愈时,公众对这种感染变得漠不关心。病原体结核分枝杆菌不断进化以抵抗拮抗药物。这导致了耐药菌株的爆发,产生了“耐多药结核病”和“广泛耐药结核病”,尽管成功率较低,但仍可以治愈。随着耐药机制的进一步发展,它最终导致无法治疗的完全耐药结核病(TDR-TB)。研究耐药性背后的分子机制将有助于我们掌握疾病的遗传学和病理生理学。在这篇综述中,我们介绍了结核分枝杆菌对药物耐受的分子机制及其在多药耐药、极端耐药和完全耐药结核病发展中的方法。